<DOC>
	<DOCNO>NCT02836600</DOCNO>
	<brief_summary>The purpose study evaluate tolerability study drug LY3039478 Japanese participant advance solid tumor .</brief_summary>
	<brief_title>A Study LY3039478 Japanese Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histological cytological evidence diagnosis solid tumor advance and/or metastatic . In judgment investigator , participant must appropriate candidate experimental therapy available standard therapy fail standard therapy appropriate . Performance status ≤1 Eastern Cooperative Oncology Group ( ECOG ) scale . Adequate organ function , include hematologic , hepatic , renal . Estimated life expectancy ≥12 week . Received previous therapy cancer within 14 21 day initial dose study drug nonmyelosuppressive myelosuppressive agent , respectively . Have serious preexist medical condition . Have current recent ( within 3 month study drug administration ) gastrointestinal disease chronic intermittent diarrhea . Have active bacterial , fungal , and/or know viral infection . Have know acute chronic leukemia current hematologic malignancy may affect interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>notch inhibitor</keyword>
</DOC>